Answers are grounded in this paper and cite their sources.
Telacebec (Q203) is a potent drug candidate under clinical development for the treatment of drug-naïve and drug-resistant tuberculosis. The first-in-human randomized, placebo-controlled, double-blind, dose-escalation Phase 1A trial (Q203-TB-PI-US001) was conducted to evaluate the safety, tolerability, and pharmacokinetics of telacebec.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: